Pharmaniaga Berhad is an investment holding company. The Company’s principal activities include manufacturing of generic pharmaceuticals, logistics and distribution, sales and marketing, supply of medical products and services, including hospital equipment, and trading and wholesaling of consumer products. The Company operates through two segments: Logistics and distribution, and Manufacturing. The Logistics and distribution segment is engaged in the distribution, trading and wholesaling of pharmaceutical and medical products, as well as supply and installation of medical and hospital equipment in Malaysia and Indonesia. It also includes supply chain management, order management and warehousing. The Manufacturing segment is engaged in manufacturing of pharmaceutical products. The product portfolio includes oral solid dosages, liquid, cream and small volume injectables. It manufactures general pharmaceutical, including penicillin, cephalosporin and over-the-counter (OTC) products.
**Do feedback to us if you see any error on the data
**Data before 2015 may not be accurate
**Dividend Yield calculated base on the last price of the year
PHARMA Dividend Yield Trend
PHARMA Quarter DY Yield
Year
Financial Year
DY_Type
Announced
EX Date
Payment Date
DY($)
Yield%
2022
31/12/2022
Third Interim
30/11/2022
08/12/2022
06/01/2023
0.006
1.10
2022
31/12/2022
Second Interim
19/08/2022
09/09/2022
04/10/2022
0.005
0.92
2022
31/12/2022
First Interim
20/05/2022
07/06/2022
06/07/2022
0.008
1.47
2021
31/12/2021
Fourth Interim
17/02/2022
07/03/2022
05/04/2022
0.05
9.17
2021
31/12/2021
Third Interim
19/11/2021
06/12/2021
29/12/2021
0.02
3.67
2021
31/12/2021
Second Interim
20/08/2021
07/09/2021
30/09/2021
0.015
2.75
2021
31/12/2021
Interim
21/05/2021
04/06/2021
06/07/2021
0.04
7.34
2020
31/12/2020
Interim
17/03/2021
30/03/2021
22/04/2021
0.01
1.83
2020
31/12/2020
Interim
19/11/2020
04/12/2020
29/12/2020
0.015
2.75
2020
31/12/2020
Interim
19/08/2020
07/09/2020
06/10/2020
0.025
4.59
2020
31/12/2020
Interim
19/05/2020
04/06/2020
30/06/2020
0.06
11.01
2019
31/12/2019
Second Interim
23/08/2019
11/09/2019
11/10/2019
0.025
4.59
2019
31/12/2019
First Interim
16/05/2019
03/06/2019
27/06/2019
0.06
11.01
2018
31/12/2018
Interim
21/02/2019
08/03/2019
10/04/2019
0.02
3.67
2018
31/12/2018
Interim
19/11/2018
03/12/2018
03/01/2019
0.05
9.17
2018
31/12/2018
Second Interim
17/08/2018
03/09/2018
18/09/2018
0.04
7.34
2018
31/12/2018
First Interim
16/05/2018
30/05/2018
20/06/2018
0.05
9.17
2017
31/12/2017
Interim
27/02/2018
13/03/2018
28/03/2018
0.06
11.01
2017
31/12/2017
Interim
15/11/2017
29/11/2017
15/12/2017
0.05
9.17
2017
31/12/2017
Interim
16/08/2017
29/08/2017
15/09/2017
0.04
7.34
2017
31/12/2017
Interim
16/05/2017
29/05/2017
07/06/2017
0.04
7.34
2016
31/12/2016
Interim
21/02/2017
07/03/2017
17/03/2017
0.03
5.50
2016
31/12/2016
Interim
21/11/2016
05/12/2016
15/12/2016
0.04
7.34
2016
31/12/2016
Interim
19/08/2016
02/09/2016
20/09/2016
0.05
9.17
2016
31/12/2016
Interim
13/05/2016
01/06/2016
28/06/2016
0.04
7.34
2015
31/12/2015
Interim
15/02/2016
01/03/2016
25/03/2016
0.07
12.84
2015
31/12/2015
Interim
26/11/2015
09/12/2015
21/12/2015
0.09
16.51
2015
31/12/2015
Interim
17/08/2015
01/09/2015
15/09/2015
0.07
12.84
2015
31/12/2015
Interim
18/05/2015
01/06/2015
25/06/2015
0.07
12.84
2014
31/12/2014
Interim
23/02/2015
09/03/2015
26/03/2015
0.12
22.02
2014
31/12/2014
Interim
21/11/2014
05/12/2014
30/12/2014
0.08
14.68
2014
31/12/2014
Interim
21/08/2014
05/09/2014
24/09/2014
0.04
7.34
2014
31/12/2014
Interim
14/05/2014
29/05/2014
16/06/2014
0.04
7.34
2013
31/12/2013
Interim
24/02/2014
10/03/2014
02/04/2014
0.062
11.38
2013
31/12/2013
Interim
19/11/2013
03/12/2013
24/12/2013
0.03
5.50
2013
31/12/2013
Second Interim
16/08/2013
30/08/2013
24/09/2013
0.0341
6.26
2013
31/12/2013
First Interim
15/05/2013
30/05/2013
28/06/2013
0.075
13.76
2012
31/12/2012
Interim
18/02/2013
04/03/2013
27/03/2013
0.1
18.35
2012
31/12/2012
Interim
06/11/2012
21/11/2012
17/12/2012
0.1
18.35
2012
31/12/2012
Second Interim
08/08/2012
23/08/2012
12/09/2012
0.075
13.76
2012
31/12/2012
First Interim
03/05/2012
16/05/2012
18/06/2012
0.075
13.76
2011
31/12/2011
Second Interim
21/02/2012
08/03/2012
28/03/2012
0.21
38.53
2011
31/12/2011
First Interim
21/12/2011
06/01/2012
26/01/2012
0.09
16.51
2010
31/12/2010
Interim
20/07/2010
02/08/2010
19/08/2010
0.1
18.35
2009
31/12/2009
Interim
05/05/2010
10/06/2010
15/07/2010
0.37
67.89
2002
31/12/2002
Interim
22/11/2002
13/12/2002
26/12/2002
0.025
4.59
PHARMA Annual DY Yield
Year
Annual DY($)
Frequency per yr
SpecialDY
Yield%
2022
0.019
3
No
3.49
2021
0.125
4
No
22.94
2020
0.11
4
No
20.18
2019
0.085
2
No
15.60
2018
0.16
4
No
29.36
2017
0.19
4
No
34.86
2016
0.16
4
No
29.36
2015
0.3
4
No
55.05
2014
0.28
4
No
51.38
2013
0.2011
4
No
36.90
2012
0.35
4
No
64.22
2011
0.3
2
No
55.05
2010
0.1
1
No
18.35
2009
0.37
1
No
67.89
2002
0.025
1
No
4.59
PHARMA Quarter Report History
Q Date
Announced
Revenue
P/L
EPS
Margin
QoQ%
YoY%
30/09/2022
24/11/2022
924,680,000
8,620,000.00
0.66
0.93
1,093.91
-82.70
30/06/2022
19/08/2022
761,100,000
722,000.00
0.06
0.09
-97.40
-94.73
31/03/2022
20/05/2022
962,170,000
27,730,000.00
2.12
2.88
-67.56
19.84
31/12/2021
17/02/2022
711,720,000
85,480,000.00
6.53
12.01
71.51
1,450.39
30/09/2021
19/11/2021
2,130,000,000
49,840,000.00
3.81
2.34
263.80
3,361.11
30/06/2021
20/08/2021
1,180,000,000
13,700,000.00
1.05
1.16
-40.80
37.27
31/03/2021
21/05/2021
793,500,000
23,140,000.00
8.84
2.92
465.56
3.30
31/12/2020
17/03/2021
634,580,000
-6,330,000.00
-2.42
-1.00
-539.58
96.46
30/09/2020
19/11/2020
624,800,000
1,440,000.00
0.55
0.23
-85.57
199.38
30/06/2020
19/08/2020
645,760,000
9,980,000.00
3.82
1.55
-55.45
7.54
PHARMA Quarter Profit Trend
PHARMA Annual Profit Trend
Cash Flow
In financial accounting, operating cash flow (OCF), cash flow provided by operations, cash flow from operating activities (CFO) or free cash flow from operations (FCFO), refers to the amount of cash a company generates from the revenues it brings in, excluding costs associated with long – term investment on capital items or investment in securities.(From Wiki)
PHARMA Annual Cash Flow
ROE & Payout Ratio
Return on equity (ROE) is a measure of financial performance calculated by dividing net income by shareholders’ equity. Because shareholders’ equity is equal to a company’s assets minus its debt, ROE is considered the return on net assets. ROE is considered a measure of the profitability of a corporation in relation to stockholders’ equity. (From Investopedia)
The payout ratio is a financial metric showing the proportion of earnings a company pays its shareholders in the form of dividends, expressed as a percentage of the company’s total earnings. On some occasions, the payout ratio refers to the dividends paid out as a percentage of a company’s cash flow. The payout ratio is also known as the dividend payout ratio. (From Investopedia)
PHARMA Annual ROE & Payout Ratio
0 Comments
Pharmaniaga Bhd is engaged in the manufacture of generic pharmaceuticals and medical devices, sales and marketing as well as the distribution of medical products and hospital equipment. The company is also involved in logistics and distribution. The group operates in three segments – Logistics and distribution, Manufacturing, and Indonesia. Maximum revenue is generated by the Logistics and distribution segment.
Pharmaniaga Bhd is engaged in the manufacture of generic pharmaceuticals and medical devices, sales and marketing as well as the distribution of medical products and hospital equipment. The company is also involved in logistics and distribution. The group operates in three segments – Logistics and distribution, Manufacturing, and Indonesia. Maximum revenue is generated by the Logistics and distribution segment.